NASDAQ · PODD
Healthcare · Medical - Devices
$153.61
Up+$1.70 (+1.11%)
Updated Nov 3, 2026, 7:46 PM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PODD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
PODD closed at $153.61 after 21 trading sessions, up 13.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $150.22 | $154.70 | $149.68 | $153.61 | 1.77M |
| Oct 30, 2026 | $154.60 | $154.95 | $149.48 | $149.68 | 1.09M |
| Oct 29, 2026 | $150.54 | $152.66 | $150.54 | $152.50 | 1.3M |
| Oct 28, 2026 | $149.28 | $150.56 | $146.62 | $148.93 | 1.04M |
| Oct 27, 2026 | $148.07 | $150.65 | $146.84 | $149.83 | 943.83K |
| Oct 26, 2026 | $149.01 | $150.735 | $146.71 | $149.26 | 1.53M |
| Oct 23, 2026 | $147.87 | $149.69 | $145.00 | $149.01 | 803.14K |
| Oct 22, 2026 | $142.47 | $148.35 | $142.47 | $148.12 | 1.21M |
| Oct 21, 2026 | $141.59 | $146.63 | $140.81 | $141.90 | 1.05M |
| Oct 20, 2026 | $143.78 | $145.00 | $141.815 | $142.64 | 1.14M |
| Oct 19, 2026 | $140.78 | $142.37 | $139.46 | $141.96 | 2.31M |
| Oct 16, 2026 | $140.46 | $143.31 | $140.22 | $141.10 | 1.62M |
| Oct 15, 2026 | $136.51 | $139.69 | $136.02 | $138.77 | 1.66M |
| Oct 14, 2026 | $139.72 | $139.745 | $133.58 | $133.93 | 2.32M |
| Oct 13, 2026 | $140.79 | $141.86 | $137.115 | $138.13 | 1.35M |
| Oct 12, 2026 | $134.81 | $140.22 | $134.81 | $139.81 | 1.33M |
| Oct 9, 2026 | $134.19 | $137.17 | $133.72 | $135.28 | 865.36K |
| Oct 8, 2026 | $133.96 | $134.60 | $132.855 | $134.47 | 1.56M |
| Oct 7, 2026 | $134.94 | $137.10 | $133.33 | $134.36 | 1.03M |
| Oct 6, 2026 | $135.77 | $136.16 | $133.725 | $134.73 | 1.71M |
| Oct 5, 2026 | $131.69 | $135.81 | $131.225 | $135.62 | 1.94M |
The latest Smart Investors Daily articles mentioning PODD.
Company
Market Activity
Research & News
PODD research
Company profile and research snapshot.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | Jefferies | Buy | — |
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Aug 6, 2026 | Leerink Partners | Market Perform | — |
| Aug 6, 2026 | Benchmark | Buy | — |
| Aug 6, 2026 | Bernstein | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChartMill · Oct 27, 2026
S&P 500 postmarket decliners after Tuesday's close included CoStar Group, NXP Semiconductors, Robinhood, Teradyne and Seagate.
Yahoo · Oct 27, 2026
Insulet will release its third-quarter earnings next week, and analysts anticipate a double-digit bottom-line growth.
Yahoo · Oct 26, 2026
Omnipod Discover launch puts Insulet’s data platform in focus Insulet (PODD) has rolled out Omnipod Discover nationwide in the US, extending a web-based data platform that earlier limited-release users and healthcare professionals had already begun to adopt. Recent trading hints at a short burst of optimism around Insulet, with a 7 day share price return of 4.97% and a 30 day gain of 9.46% to US$149.01. However, the 90 day share price return has fallen 11.02% and the 1 year total shareholder...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PODD.
